Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis
- 1 October 1996
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 135 (s49), 32-36
- https://doi.org/10.1111/j.1365-2133.1996.tb15664.x
Abstract
Topical therapies are first-line treatment for mild/limited stable plaque psoriasis. Disadvantages of currently available therapies include lack of short-term efficacy and long-term maintenance, adverse effects, and cosmetic problems. Tazarotene is a new topical retinoid which has proven to be efficacious in the treatment of mild-to-moderate plaque psoriasis. Results from a large, multicentre, pivotal study show that a once-daily application is as effective as a first-line monotherapy, providing rapid resolution of signs and symptoms and sustained therapeutic effects in some patients. Tazarotene gel is cosmetically acceptable, and is minimally absorbed systemically, with adverse events limited to local irritation.Keywords
This publication has 9 references indexed in Scilit:
- Retinoic acid in psoriasis: its value for topical therapy with and without corticosteroidsBritish Journal of Dermatology, 2006
- Topical application of 13-cis-retinoic acid in the treatment of chronic plaque psoriasisClinical and Experimental Dermatology, 1992
- The therapeutic value of retinoic acid in chronic discoid, acute guttate, and erythrodermic psoriasis: clinical observations on twenty-five patientsBritish Journal of Dermatology, 1973
- EFFECT OF RETINOIC ACID IN PSORIASIS, II.British Journal of Dermatology, 1972
- Antipsoriatic Activity of Retinoic Acid (Vitamin A Acid)Dermatology, 1971
- Topical Administration of Vitamin A Acid for Ichthyosiform Dermatoses and PsoriasisJAMA, 1969